Pedro Perez: Are We Measuring the Right Outcomes in VTE?
Pedro Perez, Senior Vascular Consultant at Argon Medical Devices, Inc., shared a post on LinkedIn:
”Are We Measuring the Right Outcomes in VTE?
In VTE, we often talk about technical success:
- Did we remove the clot?
- Did flow improve?
- Did the case go smoothly?
But the bigger question is… does that actually define success for the patient?
Because what matters long-term isn’t just what happens in the lab – it’s what happens after:
- Reduction in post-thrombotic syndrome
- Improvement in quality of life
- Decreased readmissions
- Shorter hospital stays and overall cost of care
As technology continues to evolve – from aspiration to more advanced thrombectomy approaches – we’re getting better at treating clot.
But as an industry, we need to continue shifting the conversation from procedural metrics to patient outcomes.
The next phase of VTE care won’t be defined by who has the newest device…
It will be defined by who can demonstrate meaningful, measurable impact on patients.”
Stay updated with Hemostasis Today.
-
Aug 3, 2026, 16:01Your First Steps After an ITP Diagnosis – ITP Support Association
-
Aug 3, 2026, 15:33Christina Crossette-Thambiah: Scientific Excellence and Mentorship at ISTH 2026
-
Aug 3, 2026, 15:22Connie Montgomery: Why Global Support is Essential for the HFA Black Voices Initiative
-
Aug 3, 2026, 15:18Ifeanyichukwu Ifechidere: The DOAC Monitoring Masterclass
-
Aug 3, 2026, 15:02David McIntosh: UK Plasma Action – a Founder’s Reflections
-
Aug 3, 2026, 14:49Ney Carter Borges: Targeting the Gut Microbiome to Prevent Atrial Fibrillation
-
Aug 3, 2026, 13:42Immune Thrombocytopenia: Moving Beyond Platelet Counts Toward Durable Remission
-
Aug 3, 2026, 13:28Aboo Shama Khan: Pulmonary Embolism – A Medical Emergency Every Nurse Must Recognize
-
Aug 3, 2026, 13:08Ashwin Patel: Evaluating Red Cell Function Post-Treatment in SCD Patients